aTyr Pharma to Present Poster at the American Thoracic Society 2019 International Conference
April 08, 2019 16:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, April 08, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...
aTyr Pharma Announces Fourth Quarter and Full Year 2018 Results and Provides Corporate Update
March 25, 2019 16:00 ET
|
aTyr Pharma, Inc.
Phase 1b/2a proof-of-concept clinical trial of ATYR1923 in pulmonary sarcoidosis patients initiated in December 2018 First tRNA synthetase partnership announced in March 2019 SAN DIEGO,...
aTyr Pharma Announces Poster Presentation at the 2019 American Association for Cancer Research (AACR) Annual Meeting
March 21, 2019 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, March 21, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...
aTyr Pharma to Announce Fourth Quarter and Full Year 2018 Financial Results on March 25th
March 18, 2019 16:46 ET
|
aTyr Pharma, Inc.
SAN DIEGO, March 18, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...
aTyr Pharma Announces Research Collaboration With Global Biotherapeutics Leader CSL Behring
March 11, 2019 08:00 ET
|
aTyr Pharma, Inc.
Partnership to accelerate development of IND candidates from tRNA synthetases in aTyr’s pipeline aTyr eligible to receive up to $17 million in potential option fees SAN DIEGO, March 11, 2019 ...
aTyr Pharma Announces Participation at March Investor Conferences
March 04, 2019 17:36 ET
|
aTyr Pharma, Inc.
SAN DIEGO, March 04, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...
aTyr Pharma Presents Compelling Preclinical Data Highlighting Potential of ATYR1923 to Regulate Myeloid Cell Biology During Lung Inflammation
February 27, 2019 16:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Feb. 27, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma to Present at the BIO CEO & Investor Conference
February 05, 2019 16:05 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Feb. 05, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma Announces Research Collaboration with the University of Nebraska Medical Center and Expansion of Successful Pilot Study
January 30, 2019 16:00 ET
|
aTyr Pharma, Inc.
Collaboration to advance neuropilin-2 biology and explore potential therapeutic opportunities for ATYR1923 Reinforces aTyr’s commitment to working with a strategic network of leading academic...
Pangu BioPharma (an aTyr Pharma Subsidiary) and The Hong Kong University of Science and Technology Recognized for Pioneering Work Leading to New Investigational Therapeutic for Lung Disease
January 16, 2019 16:00 ET
|
aTyr Pharma, Inc.
Researchers from The Hong Kong University of Science and Technology credited with important translational science and early discovery work Significant opportunity to replicate collaborative model to...